Cell

Quick understanding of JA Solar's 2023 annual report

Retrieved on: 
星期六, 五月 4, 2024
JA Solar Holdings, ROA, Silicon, Annual report, Cell, JA, EPS, Renewable energy

Its financial prowess shines through with impressive indicators: EPS at 2.14 yuan per share, up by 25.15%, net profit margin at 8.82% (up by 1.23 percentage points), and gross margin at18.13% (up by 3.35 percentage points).

Key Points: 
  • Its financial prowess shines through with impressive indicators: EPS at 2.14 yuan per share, up by 25.15%, net profit margin at 8.82% (up by 1.23 percentage points), and gross margin at18.13% (up by 3.35 percentage points).
  • As of Q1 2024, JA Solar has achieved a cumulative shipment of 201GW, and its production capacities across silicon wafers, cells, and modules are set to surpass 100GW each in 2024.
  • With a projected shipment target of 85-95GW, its scale manufacturing advantage will further solidify.
  • Click to get more infomation about JA Solar 2023 Annual Report.

Quick understanding of JA Solar's 2023 annual report

Retrieved on: 
星期六, 五月 4, 2024
JA Solar Holdings, Multimedia, ROA, Silicon, Annual report, Cell, JA, EPS, Renewable energy

With a weighted average ROA of 22.52%, its profitability remains industry-leading.

Key Points: 
  • With a weighted average ROA of 22.52%, its profitability remains industry-leading.
  • As of Q1 2024, JA Solar has achieved a cumulative shipment of 201GW, and its production capacities across silicon wafers, cells, and modules are set to surpass 100GW each in 2024.
  • Click to get more infomation about JA Solar 2023 Annual Report.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/quick-understanding-of-ja-solar...
    SOURCE JA Solar Technology Co., Ltd.

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Retrieved on: 
星期五, 五月 3, 2024
Cancer, Abstract, Cell, ADR, Patient, Gene, Society, IPSC, SLE, Therapy, SAN

SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that a late-breaking abstract featuring preclinical data from its FT522 program for autoimmune diseases will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, Maryland on May 7-11, 2024.

Key Points: 
  • SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that a late-breaking abstract featuring preclinical data from its FT522 program for autoimmune diseases will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, Maryland on May 7-11, 2024.
  • At the ASGCT conference, the Company will present multiple preclinical studies displaying the function of FT522 using peripheral blood mononuclear cells (PBMCs) sourced from unmatched donors with systemic lupus erythematosus (SLE).
  • These preclinical data demonstrate rapid and deep B-cell depletion, enhanced functional persistence, and elimination of alloreactive host immune cells, indicating that FT522 may deliver therapeutic benefit to patients with autoimmune diseases without requiring administration of conditioning chemotherapy.
  • Late-breaking abstracts are available on the ASGCT Annual Meeting website .

Wistar Scientists Discover New Immunosuppressive Mechanism in Brain Cancer

Retrieved on: 
星期五, 五月 3, 2024
Cell, National Cancer Institute, Macrophage, Sapienza University of Rome, Genome, Glucose, Wistar Institute, Gene, Brain, Tumor microenvironment, Wistar, Metabolomics, Neuroscience, Immunity, Ben, Medical research, Microglia, Research, Proteomics, Immunology, Histone, Malignancy, Gene expression, Neoplasm, Aurelia, Cancer, Collaborative writing, DSM-IV codes, Prognosis, Immunosuppression, Immunotherapy, Duke School, Disease, GLUT1, Patient, Metabolism, Immune system, Angelica, Vaccine

The lab’s discovery was published in the paper, “ Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma ,” in the journal Immunity.

Key Points: 
  • The lab’s discovery was published in the paper, “ Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma ,” in the journal Immunity.
  • Indeed, monocyte-derived macrophages, but not microglia, blocked the activity of T cells (immune cells that destroy tumor cells), in preclinical models and patients.
  • Glioblastoma is inherently dangerous due to its location in the brain and its immunosuppressive tumor microenvironment, which renders glioblastoma resistant to promising immunotherapies.
  • Note: The work detailed in this publication was initiated at The H. Lee Moffitt Cancer Center during Dr. Veglia’s time there and continued at Wistar.

Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List

Retrieved on: 
星期五, 五月 3, 2024
UCLA, University, Molecular genetics, University College London, Health, Kyowa Kirin, Pediatrics, Pediatric nursing, Cell, TIME, Patient, Physician, Medicine, HSC, UCL, King's College, Orchard, Therapy, Biotechnology, Pharmaceutical industry

The full list and related tributes will appear in the May 13, 2024 issue of TIME and is available online at https://time.com/collection/time100-health/ .

Key Points: 
  • The full list and related tributes will appear in the May 13, 2024 issue of TIME and is available online at https://time.com/collection/time100-health/ .
  • “I am incredibly humbled, privileged, and immensely proud to be included on this esteemed list of influential and accomplished people shaping the future of health care,” said Dr. Gaspar.
  • “Bobby is a visionary and authentic leader who inspires the very best in his colleagues and peers,” said Frank Thomas, president and chief operating officer of Orchard Therapeutics.
  • Congratulations, Bobby, and thank you for helping carry the mantel for the broader HSC gene therapy field.”

Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health

Retrieved on: 
星期五, 五月 3, 2024
Health, Neurology, Genetics, Research, Science, Pharmaceutical, Biotechnology, Neuromuscular disease, SRPT, National academy, DSM-IV codes, Hospital, Muscular dystrophy, Book, SMA, Cell, Duchenne, Disease, TIME, Patient, Sarepta Therapeutics, Gene, Society, Nationwide, Duchenne muscular dystrophy, Head, Therapy, Global health, Pharmaceutical industry

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year.
  • The TIME100 Health list recognizes the impact, innovation, and achievement of the world’s most influential individuals in health.
  • In addition to recognition on the TIME100 Health list, Dr. Mendell is a 2024 recipient of the King Faisal Prize Laureate in Medicine.
  • He is also a published author of more than 400 peer-reviewed articles and books about skeletal muscle disease, peripheral nerve disorders and gene therapy.

Latus Launches with State-of-the-Art Gene Therapy Development Technologies, Two Lead Product Candidates, and an Initial $54 Million in Series A Financing

Retrieved on: 
星期四, 五月 2, 2024
Biotechnology, Professional Services, Health, General Health, Pharmaceutical, Other Science, Research, Genetics, Science, Clinical Trials, Finance, Doctor of Philosophy, CNS, SVP, Translational medicine, MIT, Genzyme, Cochlea, Hereditary Disease Foundation, Harvard Medical School, Toxicity, HTT, Therapy, Merck, CLN2, Hospital, Safety, Biomedical Research, Samsung Biologics, CHOP, Samsung C&T Corporation, AAV, Koch Institute, Gene expression, Central nervous system, NHP, Program management, Cell, DSM-IV codes, Patient, Gene, Society, Einstein Medical Center Philadelphia, Annual general meeting, Massachusetts General Hospital, Pharmaceutical industry

Latus Bio, Inc. (“Latus”), a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), today announced its launch and an initial close of $54 million in Series A financing.

Key Points: 
  • Latus Bio, Inc. (“Latus”), a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), today announced its launch and an initial close of $54 million in Series A financing.
  • These limitations have led to the reliance on high-dose injections that cause off-target toxicity and difficulties in scalable manufacturing.
  • The Company’s management team is composed of experienced and respected leaders in gene therapy and neuroscience.
  • Her address will showcase the Company's progress and the vast potential of its technology to solve unmet needs in CNS gene therapy.

Mammoth Biosciences to Present at Annual Meeting of the American Society of Gene & Cell Therapy

Retrieved on: 
星期四, 五月 2, 2024
Science, Stem Cells, Other Science, Biotechnology, Research, Health, Genetics, Clinical Trials, CRISPR, Tissue, Hypertriglyceridemia, Cell, Liver, Patient, Gene, Society, NHP, Annual general meeting, Mammoth Biosciences, Vaccine

Mammoth Biosciences , a biotechnology company harnessing its proprietary next-generation CRISPR gene-editing platform to create potential one-time curative therapies, today announced that Lucas Harrington, Ph.D., Mammoth’s co-founder and Chief Scientific Officer, will present new preclinical data at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting in Baltimore, May 7 - 11, 2024.

Key Points: 
  • Mammoth Biosciences , a biotechnology company harnessing its proprietary next-generation CRISPR gene-editing platform to create potential one-time curative therapies, today announced that Lucas Harrington, Ph.D., Mammoth’s co-founder and Chief Scientific Officer, will present new preclinical data at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting in Baltimore, May 7 - 11, 2024.
  • The oral presentation will describe the optimization of Mammoth’s novel ultracompact CRISPR platform, and its performance in targeting the APOC3 gene, a primary genetic driver of triglyceride metabolism, in humanized mouse models and non-human primates.
  • “Our findings demonstrate the potential of Mammoth’s ultracompact CRISPR systems to deliver in vivo therapies in the liver, beginning with our lead program targeting APOC3, a key factor in familial chylomicronemia syndrome and severe hypertriglyceridemia,” Dr. Harrington said.
  • “We look forward to sharing these data with the scientific community at ASGCT, and to providing future updates as we continue to develop our novel ultracompact nucleases and associated gene-editing technologies to better target tissues beyond the liver and to positively impact the lives of patients living with genetic disease.”
    Title: Reduction in Triglycerides through a Novel Ultracompact CRISPR System: Efficacy in Mouse Models and NHP Studies
    Additionally, Janice Chen, Ph.D., co-founder and Chief Technology Officer of Mammoth, and incoming chair of the ASGCT Genome Editing Committee, will co-chair the following scientific symposium:

Trina Storage Recognized as Tier 1 Energy Storage Manufacturer by BNEF for Second Consecutive Quarter

Retrieved on: 
星期五, 五月 3, 2024
Financial management, Multimedia, Trina Solar, Tier 1, BNEF, Cell, Research, Safety, Bloomberg L.P., Growth, DNV, Renewable energy

MUNICH, May 3, 2024 /PRNewswire/ -- Trina Storage, the leading global energy storage product & solution provider, has once again secured its position as a Tier 1 energy storage manufacturer for the second quarter of 2024, according to the latest assessment by BloombergNEF (BNEF).

Key Points: 
  • MUNICH, May 3, 2024 /PRNewswire/ -- Trina Storage, the leading global energy storage product & solution provider, has once again secured its position as a Tier 1 energy storage manufacturer for the second quarter of 2024, according to the latest assessment by BloombergNEF (BNEF).
  • Trina Storage's continued dedication to research and development has propelled its success in the energy storage market.
  • By seamlessly integrating cutting-edge technologies and in-house storage products into customizable energy storage solutions, Trina Storage ensures customers benefit from optimal performance and reliability across various applications and use-cases.
  • "We are honored by BNEF's recognition of Trina Storage as a Tier 1 energy storage manufacturer for the second consecutive quarter," said Helena Li, Executive President at Trina Solar.

Trina Storage Recognized as Tier 1 Energy Storage Manufacturer by BNEF for Second Consecutive Quarter

Retrieved on: 
星期五, 五月 3, 2024
Financial management, Trina Solar, Tier 1, BNEF, Cell, Research, Safety, Bloomberg L.P., Growth, DNV, Renewable energy

MUNICH, May 3, 2024 /PRNewswire/ -- Trina Storage, the leading global energy storage product & solution provider, has once again secured its position as a Tier 1 energy storage manufacturer for the second quarter of 2024, according to the latest assessment by BloombergNEF (BNEF).

Key Points: 
  • MUNICH, May 3, 2024 /PRNewswire/ -- Trina Storage, the leading global energy storage product & solution provider, has once again secured its position as a Tier 1 energy storage manufacturer for the second quarter of 2024, according to the latest assessment by BloombergNEF (BNEF).
  • Trina Storage's continued dedication to research and development has propelled its success in the energy storage market.
  • By seamlessly integrating cutting-edge technologies and in-house storage products into customizable energy storage solutions, Trina Storage ensures customers benefit from optimal performance and reliability across various applications and use-cases.
  • "We are honored by BNEF's recognition of Trina Storage as a Tier 1 energy storage manufacturer for the second consecutive quarter," said Helena Li, Executive President at Trina Solar.